These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 27240275)

  • 1. Recent advances in the discovery of heparanase inhibitors as anti-cancer agents.
    Jia L; Ma S
    Eur J Med Chem; 2016 Oct; 121():209-220. PubMed ID: 27240275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of heparanase inhibitors for anti-cancer therapy.
    Miao HQ; Liu H; Navarro E; Kussie P; Zhu Z
    Curr Med Chem; 2006; 13(18):2101-11. PubMed ID: 16918340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of heparanase inhibitors in cancer therapy.
    Heyman B; Yang Y
    Exp Hematol; 2016 Nov; 44(11):1002-1012. PubMed ID: 27576132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Novel Class of Triazolo-Thiadiazoles as Potent Inhibitors of Human Heparanase and their Anticancer Activity.
    Baburajeev CP; Mohan CD; Rangappa S; Mason DJ; Fuchs JE; Bender A; Barash U; Vlodavsky I; Basappa ; Rangappa KS
    BMC Cancer; 2017 Mar; 17(1):235. PubMed ID: 28359266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1H NMR spectroscopic studies establish that heparanase is a retaining glycosidase.
    Wilson JC; Laloo AE; Singh S; Ferro V
    Biochem Biophys Res Commun; 2014 Jan; 443(1):185-8. PubMed ID: 24291708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity and structure-activity relationship of heparanase inhibitors: Recent advances.
    Fu K; Bai Z; Chen L; Ye W; Wang M; Hu J; Liu C; Zhou W
    Eur J Med Chem; 2020 May; 193():112221. PubMed ID: 32222663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The heparanase inhibitor PG545 is a potent anti-lymphoma drug: Mode of action.
    Weissmann M; Bhattacharya U; Feld S; Hammond E; Ilan N; Vlodavsky I
    Matrix Biol; 2019 Apr; 77():58-72. PubMed ID: 30096360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparanase: Historical Aspects and Future Perspectives.
    Khanna M; Parish CR
    Adv Exp Med Biol; 2020; 1221():71-96. PubMed ID: 32274707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate.
    Vlodavsky I; Ilan N; Naggi A; Casu B
    Curr Pharm Des; 2007; 13(20):2057-73. PubMed ID: 17627539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arylamidonaphtalene sulfonate compounds as a novel class of heparanase inhibitors.
    Rondanin R; Fochi S; Baruchello R; Bernardi T; Oliva P; Semeraro F; Simoni D; Giannini G
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4421-4425. PubMed ID: 28811133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Heparanase Regulatory Network in Health and Disease.
    Mayfosh AJ; Nguyen TK; Hulett MD
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design of a selective heparanase inhibitor as an antimetastatic agent.
    Ishida K; Hirai G; Murakami K; Teruya T; Simizu S; Sodeoka M; Osada H
    Mol Cancer Ther; 2004 Sep; 3(9):1069-77. PubMed ID: 15367701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical toolbox to interrogate Heparanase-1 activity.
    Rabinowitz ZM; Somers J; Wang Z; Cui L
    Curr Opin Chem Biol; 2024 Jun; 80():102452. PubMed ID: 38555836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Heparan Sulfate Proteoglycans and their Modifying Enzymes to Enhance Anticancer Chemotherapy Efficacy and Overcome Drug Resistance.
    Lanzi C; Zaffaroni N; Cassinelli G
    Curr Med Chem; 2017; 24(26):2860-2886. PubMed ID: 28215163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendrimer Heparan Sulfate Glycomimetics: Potent Heparanase Inhibitors for Anticancer Therapy.
    Zubkova OV; Ahmed YA; Guimond SE; Noble SL; Miller JH; Alfred Smith RA; Nurcombe V; Tyler PC; Weissmann M; Vlodavsky I; Turnbull JE
    ACS Chem Biol; 2018 Dec; 13(12):3236-3242. PubMed ID: 30480427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparanase: a target for drug discovery in cancer and inflammation.
    McKenzie EA
    Br J Pharmacol; 2007 May; 151(1):1-14. PubMed ID: 17339837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues.
    Marchetti D; Reiland J; Erwin B; Roy M
    Int J Cancer; 2003 Mar; 104(2):167-74. PubMed ID: 12569571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testing of potential glycan-based heparanase inhibitors in a fluorescence activity assay using either bacterial heparinase II or human heparanase.
    Schoenfeld AK; Vierfuß S; Lühn S; Alban S
    J Pharm Biomed Anal; 2014 Jul; 95():130-8. PubMed ID: 24667567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparanase as a molecular target of cancer chemotherapy.
    Simizu S; Ishida K; Osada H
    Cancer Sci; 2004 Jul; 95(7):553-8. PubMed ID: 15245589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The heparanase/heparan sulfate proteoglycan axis: A potential new therapeutic target in sarcomas.
    Cassinelli G; Zaffaroni N; Lanzi C
    Cancer Lett; 2016 Nov; 382(2):245-254. PubMed ID: 27666777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.